– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for "Alnylam 5x15" Target –

- Conference Call Today at 8:30 a.m. EST PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the acquisition of Novartis' entire RNAi research and development portfolio and associated

PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Research Corporation ( NASDAQ : ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ( NASDAQ : NBI) as part of the annual re-ranking which

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced Phase 2 clinical data on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA), and the first clinical data on a triple combination of JNJ-3989, JNJ-6379,

PASADENA, Calif. --(BUSINESS WIRE)--Aug. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator

Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics PASADENA, Calif. — December 18, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has signed a research collaboration and license

PASADENA, Calif. & HOPKINTON, Mass. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. ( NASDAQ : ARWR) and Spring Bank Pharmaceuticals, Inc. ( NASDAQ : SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory

Fibrosis regression observed in 50% of patients receiving fazirsiran Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups Results

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM ) platform.